** Omnicell's OMCL.O shares down 7% at $42.81 Tues as medical software co seeks capital raise
** Fort Worth, Texas-based firm early Tues said offering privately $150 mln 5-yr convertible bonds (CBs)
** Co expects to use portion of net proceeds to pay for capped calls, remainder, along with cash, to repurchase up to $400 mln of its outstanding 0.25% CBs due 2025
** On Oct 29, shares soared 32% to close at $53.05 after co posted big adj Q3 EPS beat and hiked its FY 2024 earnings outlook
** With move on Tues, shares up 14% YTD for market value of ~$2 bln, per LSEG
** Of 9 analysts covering OMCL, 3 rate "buy", rest "hold"; median PT of $60 up from $44.50 a month ago
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper.thomsonreuters.com@reuters.net lance.tupper@tr.com 1-646-279-6380))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。